Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR once-daily evening dosing versus quetiapine IR twice-daily dosing in stable schizophrenia
2010-020579-21Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of quetiapine in schizophrenia (2 arms), sponsored by AstraZeneca. Primary endpoint: CogState composite cognitive performance. Started Jul 2010; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-020579-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020579-21.